A Review of the Potential of Hemoperfusion for the Treatment of Patients with Respiratory Infectious Diseases with COVID-19 Approach

Mohammadreza Moshari; Mehrdad Mesbah Kiaei; Mohammad Hassani

doi:10.18502/aacc.v7i3.6906

Mohammadreza Moshari Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehrdad Mesbah Kiaei Department of Anesthesiology and Pain medicine, Rasol Akram Hospital, Iran university of Medical Sciences, Tehran, Iran.
Mohammad Hassani Department of Vascular and Endovascular Surgery, Aiatolla taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

DOI: https://doi.org/10.18502/aacc.v7i3.6906

Keywords: COVID-19; Hemoperfusion; Inflammatory storms

Abstract

Severe infection with COVID-19 disease can be associated with respiratory failure, kidney disorders, and in more advanced stages, organ failure and death. Unfortunately, there is currently no definitive cure for this disease, and damage to the immune system caused by inflammatory storms leads to widespread and varied complications that make an early diagnosis of the disease difficult. Therefore, eliminating or inhibiting the production of factors involved in inflammatory storms can be effective in improving the clinical condition of patients. According to specialized studies on the role of hemoperfusion in inhibiting advanced levels of COVID-19 disease, the present study was performed to investigate the use of hemoperfusion as a potential treatment option for this disease.